IRIS
BERTOLI, ADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.083
EU - Europa 2.283
AS - Asia 1.036
SA - Sud America 19
AF - Africa 12
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 8
Totale 25.450
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.078
SG - Singapore 451
IT - Italia 357
DE - Germania 346
SE - Svezia 318
UA - Ucraina 285
CN - Cina 282
PL - Polonia 234
IE - Irlanda 233
KR - Corea 224
FR - Francia 184
GB - Regno Unito 112
RU - Federazione Russa 80
FI - Finlandia 71
CZ - Repubblica Ceca 20
BE - Belgio 18
HK - Hong Kong 13
JP - Giappone 12
VN - Vietnam 12
NL - Olanda 10
AU - Australia 8
CH - Svizzera 8
CL - Cile 8
IN - India 7
KG - Kirghizistan 7
EU - Europa 6
BR - Brasile 5
ET - Etiopia 5
PK - Pakistan 5
BD - Bangladesh 4
CA - Canada 4
IQ - Iraq 4
AR - Argentina 3
CO - Colombia 3
TR - Turchia 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
DK - Danimarca 2
MN - Mongolia 2
TW - Taiwan 2
ZA - Sudafrica 2
AL - Albania 1
CM - Camerun 1
EG - Egitto 1
ES - Italia 1
IL - Israele 1
KZ - Kazakistan 1
MX - Messico 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
RO - Romania 1
SA - Arabia Saudita 1
SC - Seychelles 1
TH - Thailandia 1
TN - Tunisia 1
Totale 25.450
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.680
Wilmington 6.067
Houston 4.704
Fairfield 722
Chandler 606
Ann Arbor 533
Singapore 393
Seattle 302
Ashburn 300
Jacksonville 242
Cambridge 231
Kraków 231
Dublin 210
Rome 180
Medford 158
Dearborn 112
New York 108
Santa Clara 107
Beijing 103
Zhengzhou 75
Lawrence 74
San Diego 52
Milan 45
Menlo Park 36
Mülheim 35
Moscow 34
Palo Alto 25
Creede 22
Colorado Springs 20
Boardman 18
San Francisco 18
Brussels 17
Falls Church 17
Munich 16
University Park 15
Nanjing 14
Olomouc 14
London 13
Phoenix 12
Shanghai 12
Norwalk 11
Cedarhurst 10
Dong Ket 9
Helsinki 9
Hong Kong 9
Guangzhou 8
Redwood City 8
Verona 8
Bari 7
Hefei 7
Jinan 7
Los Angeles 7
Mountain View 7
Brno 6
Kunming 6
Magenta 6
Seoul 6
Coventry 5
Manitou Springs 5
Nanchang 5
Palermo 5
Saint Petersburg 5
Fuzhou 4
Hangzhou 4
Kilburn 4
Nuremberg 4
Nürnberg 4
San Mateo 4
Wuhan 4
Adelaide 3
Amsterdam 3
Baghdad 3
Bogotá 3
Council Bluffs 3
Detroit 3
Hounslow 3
Indiana 3
Lahore 3
Lappeenranta 3
Lausanne 3
Nanning 3
Naples 3
Novokuznetsk 3
Padova 3
Perugia 3
Prescot 3
Redmond 3
St. George 3
São Paulo 3
Tokyo 3
Acton 2
Albano Laziale 2
Belgrade 2
Bengaluru 2
Binasco 2
Brescia 2
Camponogara 2
Center 2
Central 2
Chengdu 2
Totale 22.840
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 509
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 470
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 447
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 444
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 441
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 433
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 432
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 431
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 430
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 427
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 426
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 425
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 424
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 423
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 422
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 418
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 417
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 416
Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster 415
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 411
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 407
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 402
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 401
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 399
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 396
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 386
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 385
A case of Italian HIV-2 infection: a genetic analysis 380
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 380
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 378
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 377
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 375
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 375
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 370
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 369
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 368
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 368
The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages 368
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 366
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 365
Temporal change in the use of genotypic resistance testing over the years 1999--2003 364
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 362
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 359
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 358
null 357
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 356
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 356
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 354
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 347
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 347
Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART 342
HIV-1 non-B subtypes in Italy: a growing trend 339
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 335
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome 330
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 330
Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 323
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 321
The V118I mutation as a marker of advanced HIV infection and disease progression 321
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 317
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 311
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 308
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 293
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 272
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 266
HIV MDR is still a relevant issue despite its dramatic drop over the years 171
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 168
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 108
Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis 105
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 89
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 86
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 81
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 74
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 61
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 56
An HIV Type 2 Case Series in Italy: A Phylogenetic Analysis 49
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 48
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 48
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 45
Infection Rate of Respiratory Viruses in the Pandemic SARS-CoV-2 Period Considering Symptomatic Patients: Two Years of Ongoing Observations 38
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 34
Genetic heterogenicity of HIV-1 protease in drug-naive and drug-treated HIV-positive patients 27
Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches 24
Factors predictive of virological response after genotyping resistance test (GRT): data from an unselected cohort 24
Prevalence of HDV infection in Central Italy has remained stable across the last two decades with dominance of sub-genotypes 1 and characterized by elevated viral replication 19
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 17
Factors predictive of multinucleoside analogue-resistance mutations in an unselected cohort of HAART-failed patients. 16
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 16
Temporal characterization of frequency of drug-resistance associated mutations in the HIV-1 protease and reverse transcriptase 15
Time to detection and loss of M184 genotypic mutation among HIV patients treated with 3TC and failing an HAART regimen 14
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 14
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 14
Cross-resistance among NNRTIs: evaluation of the option of recycling Efavirenz after Nevirapine failure 12
Identification of the Minimal Conserved Structure of the HIV-Reverse Transcriptase under the Presence and Absence of Drug Pressure 11
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation 10
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings 10
Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes 9
Totale 25.757
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.571
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.571
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.209 0 0 418 557 544 705 589 537 544 523 381 411
2020/20213.763 404 430 439 477 340 425 549 355 80 79 128 57
2021/20221.140 60 79 106 67 34 88 48 48 214 83 45 268
2022/20231.510 121 148 114 192 114 291 91 153 123 51 77 35
2023/2024462 59 10 32 21 49 107 25 21 10 20 6 102
2024/2025751 95 523 133 0 0 0 0 0 0 0 0 0
Totale 25.757